OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	18.63	29.88	11.54
Cash & Short-Term Investments	18.63	29.88	11.54
Cash Growth	-	158.82%	-
Prepaid Expenses	5.16	3.89	2.08
Total Current Assets	23.8	33.77	13.62
Property, Plant & Equipment	1.63	1.91	2.05
Other Long-Term Assets	0.05	0.06	0.33
Total Assets	25.47	35.73	16
Accounts Payable	8.26	3.42	2.52
Accrued Expenses	4.51	3.66	2.87
Current Portion of Leases	0.22	0.21	0.15
Total Current Liabilities	12.98	7.29	5.54
Long-Term Leases	0.36	0.47	0.49
Total Liabilities	19.23	7.75	6.03
Common Stock	0	0	0
Additional Paid-In Capital	2.15	0.21	2.66
Retained Earnings	-125.73	-102.05	-57.07
Total Common Equity	-123.58	-101.84	-54.42
Shareholders' Equity	6.25	27.98	9.97
Total Liabilities & Equity	25.47	35.73	16
Total Debt	6.43	0.67	0.64
Net Cash (Debt)	12.2	29.2	10.91
Net Cash Growth	-	167.76%	-
Net Cash Per Share	9.16	24.25	-
Filing Date Shares Outstanding	1.34	1.33	-
Total Common Shares Outstanding	1.34	1.33	-
Working Capital	10.81	26.48	8.08
Book Value Per Share	-92.31	-76.35	-
Tangible Book Value	-123.58	-101.84	-54.42
Tangible Book Value Per Share	-92.31	-76.35	-
Machinery	1.02	1.01	0.85
Leasehold Improvements	1.09	1.09	1

Source: S&P Capital IQ. Standard template. Financial Sources.